A5006400001- Chronic Myeloid Leukemia Treatments
- Chronic Lymphocytic Leukemia Research
- Eosinophilic Disorders and Syndromes
- Acute Myeloid Leukemia Research
- IL-33, ST2, and ILC Pathways
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Acute Lymphoblastic Leukemia research
- Cystic Fibrosis Research Advances
- Cytokine Signaling Pathways and Interactions
- Lymphoma Diagnosis and Treatment
- Kruppel-like factors research
- Pluripotent Stem Cells Research
- Click Chemistry and Applications
- Fungal Plant Pathogen Control
- CRISPR and Genetic Engineering
- MicroRNA in disease regulation
- HER2/EGFR in Cancer Research
- Blood Coagulation and Thrombosis Mechanisms
- Glioma Diagnosis and Treatment
- Genetic factors in colorectal cancer
- Tracheal and airway disorders
- Neonatal Respiratory Health Research
- Genomics and Rare Diseases
- Child Nutrition and Water Access
- Renal and related cancers
Centre Hospitalier Universitaire de Poitiers
2015-2024
Fédération Hospitalo-Universitaire, Paris Center for Microbiome Medicine
2020-2024
Inserm
2014-2023
Université Paris-Saclay
2023
Université de Poitiers
2010-2022
Centre National de la Recherche Scientifique
1992-2020
Service de la Santé Publique
2020
Institut Bergonié
2019
State Key Laboratory of Cancer Biology
2017
Université Paris-Sud
2011-2014
More than half of patients with chronic-phase chronic myelogenous leukemia (CP-CML) in complete molecular response (CMR) experience relapse after imatinib discontinuation. We investigated loss major (MMR) as a criterion for resuming therapy.A multicenter observational study (A-STIM [According to Stop Imatinib]) evaluating MMR persistence was conducted 80 CP-CML who had stopped prolonged CMR.Median time from initiation discontinuation 79 months (range, 30 145 months);median duration CMR...
Journal Article Modification of enzymatic-ally amplified DNA for the detection point mutations Get access A. Haliassos, Haliassos Institut de Pathologie Moléculaire, CHU Cochin 24 rue du F bS St Jacques, F-75014, Pans, France Search other works by this author on: Oxford Academic PubMed Google Scholar J.C. Chomel, Chomel L. Tesson, Tesson M. Baudis, Baudis J. Kruh, Kruh Kaplan, Kaplan Kitzis * To whom correspondence should be addressed Nucleic Acids Research, Volume 17, Issue 9, 11 May 1989,...
We have collated the results of cystic fibrosis (CF) mutation analysis conducted in 19 laboratories France. analyzed 7,420 CF alleles, demonstrating a total 310 different mutations including 24 not reported previously, accounting for 93.56% genes. The most common were F508del (67.18%; range 61–80), G542X (2.86%; 1–6.7%), N1303K (2.10%; 0.75–4.6%), and 1717-1G>A (1.31%; 0–2.8%). Only 11 had relative frequencies >0.4%, 140 found on small number alleles (from 29 to two), 154 unique. These data...
The detection of point mutations correlated with diseases, in enzymatically amplified DNA sequences (Polymerase Chain Reaction), is currently performed by digestion PCR products when an existing restriction site disappears at least one allele the mutated sequence or specific radiolabeled probes all other cases. These methods are most sensitive but they cannot detect a mutation if it present less than 5% studied cells. We describe here method based on introduction artificial site, using...
Abstract We aimed to study the prognostic impact of mutational landscape in primary and secondary myelofibrosis. The included 479 patients with myelofibrosis recruited from 24 French Intergroup Myeloproliferative Neoplasms (FIM) centers. molecular was studied by high-throughput sequencing 77 genes. A Bayesian network allowed identification genomic groups whose a multistate model considering transitions 3 conditions: myelofibrosis, acute leukemia, death. Results were validated using an...
Background Micro-RNAs (miRNAs) control gene expression by destabilizing targeted transcripts and inhibiting their translation. Aberrant of miRNAs has been described in many human cancers, including chronic myeloid leukemia. Current first-line therapy for newly diagnosed leukemia is imatinib mesylate, which typically produces a rapid hematologic response. However the effect on miRNA vivo not thoroughly examined.Design Methods Using TaqMan Low-Density Array system, we analyzed blood samples...
During the last decade, use of tyrosine kinase inhibitor (TKI) therapy has modified natural history chronic myeloid leukemia (CML) allowing an increase overall and disease-free survival, especially in patients whom molecular residual disease becomes undetectable. However, it been demonstrated that BCR-ABL1- expressing leukemic stem cells (LSCs) persist deep response. It also shown discontinuation Imatinib leads to a relapse majority cases. To determine possible relationship between these two...
Abstract Among myeloproliferative neoplasms, polycythemia vera (PV) and essential thrombocythemia (ET) are the 2 entities associated with most chronic disease course. Leukemic evolution occurs rarely but has a grim prognosis. The interval between diagnosis leukemic is highly variable, from few years to >20 years. We performed molecular evaluation of 49 transformations PV ET by targeted next-generation sequencing. Using hierarchical classification, we identified 3 groups distinct time...
Jean-Claude Chomel and Ali G. Turhan Service d'Hématologie et Oncologie Biologique, CHU de Poitiers, France, Inserm U935, Université France Received: September 21, 2011; Accepted: 22, Published: Keywords: CML, tyrosine kinase inhibitors, leukemic stem cells, persistency, quiescence, undetectable molecular disease Correspondence: A.G. Turhan, email: // Abstract Targeted therapies of chronic myeloid leukemia (CML) using inhibitors (TKI) have profoundly changed the natural history with a major...
STAT5 fulfills essential roles in hematopoietic stem cell (HSC) self-renewal and chronic myeloid leukemia (CML), a prototypical malignancy. However, the specific contributions of two related genes STAT5A STAT5B have not been determined. In this study, we used RNAi-based strategy to establish participation these CML disease persistence following targeted therapy. We showed that STAT5A/STAT5B double-knockdown triggers apoptosis suppresses both normal HSC long-term clonogenic potential....
Recent studies have demonstrated a relationship between the expression of stem cell-associated genes and relapses in glioblastoma (GBM), suggesting key role for tumor cells this process. Although there is increasing interest field, glioma (GSCs) are still poorly characterized, their 'stemness' state factors maintaining these properties remain largely unknown. We performed an profiling analysis pluripotency gliomaspheres derived from 11 patients. Comparative GSCs H1 H9 human embryonic as well...
Radioresistant glioblastoma stem cells (GSCs) contribute to tumor recurrence and identification of the molecular targets involved in radioresistance mechanisms is likely enhance therapeutic efficacy. This study analyzed DNA damage response following ionizing radiation (IR) 10 GSC lines derived from patients. was quantified by Comet assay repair effectors were assessed Low Density Array. The effect RAD51 inhibitor, RI-1, evaluated comet annexin V assays. While all displayed efficient...
Although it is generally acknowledged that cytokines regulate normal hematopoiesis in an autocrine/paracrine fashion, their possible role chronic myelogenous leukemia (CML) and resistance to imatinib mesylate treatment remain poorly investigated. Here, we report CD34(+) progenitors from patients with CML at diagnosis are selectively targeted by the cytokine/alarmin interleukin (IL)-33. Indeed, upregulate cell surface expression of IL-33-specific receptor chain ST2, proliferate produce...
Bone marrow (BM)-derived mesenchymal stromal cells (MSCs) frequently display alterations in several hematologic disorders, such as acute lymphoid leukemia, myeloid leukemia (AML), and myelodysplastic syndromes. In leukemias, it is not clear whether MSC contribute to the development of malignant clone or they are simply effect tumor expansion on microenvironment. We extensively investigated characteristics MSCs isolated from BM patients with de novo AML at diagnosis (L-MSCs) terms phenotype...
Immunological mechanisms of treatment-free remission (TFR) in chronic myeloid leukaemia (CML) are poorly defined and, to date, no correlation between successful TFR and CD8(+) T-cell subsets has been found. We analysed a new identified human subset T-cells, namely innate CML patients with ≥ 2 years. demonstrated dramatic increase functionally active T-cells these as compared control subjects under tyrosine kinase inhibitors. Moreover, we found positive frequencies natural killer cells,...
Background Long‐term treatment‐free remission (TFR) represents a new goal for chronic myeloid leukemia (CML). In clinical practice, tyrosine kinase inhibitor (TKI) dose reductions can be considered means of preventing adverse effects and improving quality life. We hypothesized that administration low‐dose TKIs before treatment discontinuation does not impair TFR in patients with CML who have deep molecular response (DMR, ≥MR 4 ). Methods conducted retrospective analysis 77 discontinued TKIs....